BioWorld Senior Analyst Karen Carey explores the newest data and where it is leading. Hosted on Acast. See <a style="color: grey;" href="https://acast.com/privacy" target= "_blank" rel="noopener noreferrer">acast.com/privacy</a> for more information.

BioWorld Senior Analyst Karen Carey explores the newest data and where it is leading. Hosted on Acast. See acast.com/privacy for more information.

BioWorld Senior Analyst Karen Carey explores the newest data and where it is leading. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Biopharma’s correction? 2022 1Q investments are both up and down

One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.

Share Biopharma’s correction? 2022 1Q investments are both up and down

Sign up to save your podcasts

Biopharma’s correction? 2022 1Q investments are both up and down

Biopharma’s correction? 2022 1Q investments are both up and down

More shows like The BioWorld Insider Podcast

Wait Wait... Don't Tell Me!

Planet Money

Freakonomics Radio

Acquired

Pod Save America

The Daily

Up First from NPR

The Readout Loud

All-In with Chamath, Jason, Sacks & Friedberg

Business Of Biotech

BioCentury This Week

Hard Fork

The Ezra Klein Show

Biotech Hangout

Cell & Gene: The Podcast